Skip to main content

Closed

AVTX: Avalo Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Operating margin-134164.4%

ROIC-89.3%

Financially safe

Stretched

Debt / equity0.03×

Interest coverage0.0×

Current ratio7.66×

Avalo Therapeutics, Inc.

AVTXNASDAQ Capital Market·USD·Closed

Avalo Therapeutics, Inc.

AVTXNASDAQ·USD·Closed

$18.25

−5.88%

$18.25

−$1.14 (5.88%)

52W Range

64thpctl

Volume

0.44×avg

Mkt Cap

206.12MUSD

P/E

-3.1TTM

Div Yield

–ann

52W Range

64thpctl

Volume

0.44×avg

Market Cap

206.12MUSD

P/E Ratio

-3.1TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings